Advanced search
Publication Cover
Xenobiotica
the fate of foreign compounds in biological systems
Volume 49, 2019 - Issue 6
Submit an article Journal homepage
667
Views
9
CrossRef citations to date
0
Altmetric
Animal Pharmacokinetics and Metabolism

Disposition and metabolism of [14C]lemborexant, a novel dual orexin receptor antagonist, in rats and monkeys

Takashi UenoDrug Metabolism and Pharmacokinetics, Eisai Co., Ltd, Tsukuba, Ibaraki, JapanCorrespondence[email protected]
ORCID Iconhttp://orcid.org/0000-0002-2859-5865
ORCID Icon,
Tomomi IshidaDrug Metabolism and Pharmacokinetics, Eisai Co., Ltd, Tsukuba, Ibaraki, Japan
&
Kazutomi KusanoDrug Metabolism and Pharmacokinetics, Eisai Co., Ltd, Tsukuba, Ibaraki, Japan
Pages 688-697 | Received 13 Apr 2018, Accepted 26 May 2018, Published online: 05 Jul 2018

Citations (9)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Gary Zammit & Andrew Krystal. (2021) Evaluating lemborexant for the treatment of insomnia. Expert Opinion on Pharmacotherapy 22:10, pages 1235-1243.
Read now

Articles from other publishers (8)

Kenya Watanabe, Shingen Misaka, Keiko Kanno‐Nozaki, Takaaki Chiyoda, Yuhei Suzuki, Akiko Sato, Takahiro Suto, Junko Kuroda, Kenju Shimomura, Itaru Miura & Hirooki Yabe. (2023) Effect of lemborexant on pharmacokinetics of clozapine: A potential drug–drug interaction mediated by time‐dependent inhibition of CYP3A4. British Journal of Clinical Pharmacology 90:1, pages 354-359.
Crossref
Chandra Prakash. 2023. Overcoming Obstacles in Drug Discovery and Development. Overcoming Obstacles in Drug Discovery and Development 223 238 .
Carsten T. Beuckmann, Hiroyuki Suzuki, Erik S. Musiek, Takashi Ueno, Toshitaka Sato, Masahiro Bando, Yoshihide Osada & Margaret Moline. (2021) Evaluation of SAMP8 Mice as a Model for Sleep-Wake and Rhythm Disturbances Associated with Alzheimer’s Disease: Impact of Treatment with the Dual Orexin (Hypocretin) Receptor Antagonist Lemborexant. Journal of Alzheimer's Disease 81:3, pages 1151-1167.
Crossref
Ishani Landry, Jagadeesh Aluri, Nancy Hall, Gleb Filippov, Satish Dayal, Margaret Moline & Larisa Reyderman. (2021) Effect of severe renal impairment on pharmacokinetics, safety, and tolerability of lemborexant. Pharmacology Research & Perspectives 9:2.
Crossref
Ishani Landry, Kenya Nakai, Jim Ferry, Jagadeesh Aluri, Nancy Hall, Bojan Lalovic & Margaret L. Moline. (2020) Pharmacokinetics, Pharmacodynamics, and Safety of the Dual Orexin Receptor Antagonist Lemborexant: Findings From Single‐Dose and Multiple‐Ascending‐Dose Phase 1 Studies in Healthy Adults. Clinical Pharmacology in Drug Development 10:2, pages 153-165.
Crossref
Michinori KoebisuNoriyuki KoyamaMaika NishidaKenzo Muramoto. (2021) Preclinical and clinical efficacy of orexin receptor antagonist Lemborexant (Dayvigo<sup>®</sup>) on insomnia patients新規オレキシン受容体拮抗薬レンボレキサント（デエビゴ錠<sup>®</sup> 2.5 mg，5 mg，10 mg）の薬理効果と不眠症患者における臨床的有用性. Folia Pharmacologica Japonica 156:2, pages 114-119.
Crossref
Takashi Ueno, Tomomi Ishida, Jagadeesh Aluri, Michiyuki Suzuki, Carsten T. Beuckmann, Takaaki Kameyama, Shoji Asakura & Kazutomi Kusano. (2021) Disposition and Metabolism of [ 14 C]Lemborexant in Healthy Human Subjects and Characterization of Its Circulating Metabolites . Drug Metabolism and Disposition 49:1, pages 31-38.
Crossref
Christina Grumann, Laura M. Huppertz, Philippe Bisel, Verena Angerer & Volker Auwärter. (2019) Method validation and preliminary pharmacokinetic studies on the new designer stimulant 3‐fluorophenmetrazine (3‐FPM). Drug Testing and Analysis 11:7, pages 1009-1017.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.